Trials / Completed
CompletedNCT05140200
Study of GSK3511294 in Healthy Chinese Participants
An Open-label, Single Dose Study to Investigate the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Two Dose Levels of GSK3511294 Administered Subcutaneously in Chinese Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This single dose pharmacokinetic (PK) study aims to investigate the PK, safety, tolerability and immunogenicity of two dose levels of GSK3511294 administered subcutaneously in Chinese healthy participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK3511294 | GSK3511294 will be administered. |
Timeline
- Start date
- 2021-12-10
- Primary completion
- 2022-12-23
- Completion
- 2022-12-23
- First posted
- 2021-12-01
- Last updated
- 2025-01-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05140200. Inclusion in this directory is not an endorsement.